Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025. Read the press release here: https://bit.ly/3DRGAKC

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA? and OPDIVO?. Read the press release here: https://bit.ly/3XYMa4F

The 37th Annual Roth Conference begins today, and our management team is looking forward to kicking off scheduled 1-on-1 meetings. Interested investors should contact their ROTH representative or submit a registration request: https://bit.ly/4bncDys

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia. Read the press release here: https://bit.ly/4isPrl4

Actinium announced that the first clinical trial under its previously announced Cooperative Research and Development Agreement with the National Cancer Institute (NCI)?for Actimab-A has been initiated. Dr. Avinash Desai, Actinium's Chief Medical Officer, commented, "We are incredibly excited that the first Actimab-A trial initiated under our CRADA with the NCI is this triplet combination with Venetoclax and Taiho's ASTX-727. While Ven-HMA has positively impacted outcomes in AML, a significant number of patients have poor responses or relapse quickly resulting in dismal outcomes. We believe Actimab-A's potentially synergistic, and mutation agnostic mechanism of action can improve clinical outcomes for these patients by producing deeper remissions, including measurable residual disease negativity, that are more durable. We are eager to collaborate with NCI on this important study to evaluate earlier intervention with a CD33 targeted radiotherapy in patients with AML." Dive into the announcement:?https://lnkd.in/gvM8pPiA?

Actinium (NYSE: ATNM) management will be attending the 37th Annual Roth Conference and available for 1-on-1 meetings on March 17th and 18th. Interested investors should contact their ROTH representative or submit a registration request: https://bit.ly/4bncDys ROTH Capital Partners

New from Targeted Oncology: Actimab-A Triplet Trial Launches in Frontline AML.?A phase 1 trial is evaluating Actimab-A, venetoclax, and ASTX-727 in frontline AML, with initial data expected later this year. Read the article:?https://lnkd.in/gJMUexZ5

Actinium Pharmaceuticals (NYSE: ATNM) to Participate at the 37th Annual Roth Conference. Read the press release here: https://bit.ly/4bN930D ROTH Capital Partners

Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML. Read the press release here: https://bit.ly/3DAjrfJ

Actinium Pharmaceuticals (NYSE: ATNM) Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024. Read the press release here: https://bit.ly/3OgVsUA